Three areas on chromosomes contain prostate cancer aggressive genes

July 26, 2000

Prostate cancer is the most common cancer among U.S. males. It is the second leading cause of cancer death -- trailing only lung cancer -- in that group. In the year 2000, approximately 180,400 men nationally will be diagnosed with prostate cancer, a disease accounting for about 31,900 deaths annually.

Little is currently known about what makes some prostate cancer biologically aggressive and more likely to progress to metastatic and potentially lethal disease. One compelling possibility is that genetic factors help drive the mechanisms underlying prostate cancer aggressiveness.

Now, for the first time, researchers have taken a direct measure of prostate cancer aggressiveness in a genome-wide scan. The results, which appear in the July issue of the "American Journal of Human Genetics," suggest three candidate regions that give evidence for linkage to prostate cancer aggressive genes. They are located on chromosomes 5q, 7q, and 19q.

"This indicates that one or more of these candidate regions may contain genes that influence the progression of prostate cancer from latent to invasive disease," said John S. Witte, lead author and associate professor of epidemiology and biostatistics at Case Western Reserve University's School of Medicine. "Identifying such genes would be extremely valuable for elucidating the biologic mechanisms underlying prostate cancer progression and for determining treatment in men diagnosed with the disease," he said.

The researchers ranked cancer aggressiveness with the Gleason score, a key pathological measure assigned to a prostate tumor. Gleason score reflects the patterns of tissue architecture observed by a pathologist in two prostate biopsy or surgical samples.

Low Gleason scores indicate that the tumor cells are well differentiated and organized into glandular structures. In contrast, higher scores signify less differentiation of the tumor cells: they appear solid and dissipate together. Poor differentiation, and, hence, a high Gleason score, is a strong prospective gauge of which tumors will penetrate the prostate capsule, invade the seminal vesicles, and spread to the lymph nodes. Therefore, the researchers determined, genes linked to Gleason score -- and hence tissue architecture -- could serve as molecular markers of prostate cancer aggressiveness.

To investigate this possibility, the researchers from CWRU, Washington University in St. Louis, and the Marshfield Medical Research and Education Foundation in Marshfield, Wisconsin, evaluated genetic markers spaced across the genomes of 513 brothers with prostate cancer to determine whether these markers are inherited along with a predisposition to more aggressive disease, as indicated by Gleason score. The researchers found evidence for linkage with Gleason score in three regions on chromosomes 5q, 7q, and 19q.
-end-
Other authors were Katrina A. B. Goddard, David V. Conti, Robert C. Elston from CWRU; Jennifer Lin, Brian K. Suarez, and William J. Catalona from Washington University; and Karl W. Broman, James K. Burmester, and James L. Weber from Marshfield.

Case Western Reserve University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.